Turkovac
Vaccine against COVID-19
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Other names | ERUCOV-VAC |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
.svg){kind=small} COVID-19 portal |
Turkovac[1] (pronunciation: ['tɜ:rkəvæk]) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.
Clinical trials
In November 2020, TURKOVAC started on phase I trials with 44 participants in Turkey.[2]
In February 2021, TURKOVAC started on phase II trials with 250 participants in Turkey.[3]
In June 2021, TURKOVAC started on phase III trials with 40,800 participants in Turkey.[4] As of 2023[update] phase III trials continue.[5]
Authorization
On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed.[6] On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.[7]
- ^ Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.
- ^ Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)" at ClinicalTrials.gov
- ^ Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19 " at ClinicalTrials.gov
- ^ "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.
- ^ "ClinicalTrials.gov". www.clinicaltrials.gov. Retrieved 16 January 2024.
- ^ "Turkey issues emergency-use authorization for its domestically produced vaccine". The New York Times. 22 December 2021. Retrieved 28 December 2021.
- ^ "Turkey authorises use of own Turkovac Covid-19 vaccine". France 24. 23 December 2021. Retrieved 24 December 2021.
Scholia has a profile for TURKOVAC (Q106532118).
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
